The interim trade deal between India and the US is "almost complete," as stated by US officials following a meeting between External Affairs Minister S. Jaishankar and US Secretary of State Marco Rubio in Manila.
US Secretary of State Marco Rubio is expected to visit India later this year.
Discussions between Jaishankar and Rubio focused on key areas of the Comprehensive Global Strategic Partnership, including trade, energy, defense, critical minerals, and artificial intelligence.
US President Donald Trump announced a new policy to onshore drug manufacturing, imposing zero tariffs on imported generic drugs for two years, followed by 100% and then 200% tariffs, a move that could impact India.
India is the largest exporter of generic drugs to the US, supplying nearly 40% of medicines sold by volume.
Detailed Insights:
The meeting took place on the sidelines of the ASEAN and East Asia Summit (EAS) meetings in Manila, highlighting the regional and global context of the bilateral discussions.
The interim trade deal aims to reduce tariffs and enhance economic cooperation, with India agreeing to cut duties on US industrial and agricultural goods.
India has committed to purchasing approximately $500 billion worth of US goods, including energy products and technology, over five years.
The US also removed a 25% penalty tariff on India, previously imposed due to India's imports of Russian oil, contingent on India ceasing such purchases.
The Comprehensive Global Strategic Partnership between India and the US is built on shared democratic values and encompasses broad cooperation across defense, technology, and trade.
Discussions also included finalizing key defense agreements, referring to the foundational agreements like LEMOA, COMCASA, and BECA, which facilitate deeper military cooperation.
The US drug manufacturing policy, effective August 1, 2026, seeks to incentivize domestic production by gradually increasing tariffs on imported generic drugs.
Analysts suggest that the impact on Indian pharmaceutical companies might be limited due to India's significant cost advantage in manufacturing generic medicines and the operational structure of Indian firms in the US.
Key Concepts Involved:
Interim Trade Deal: A preliminary agreement between two countries to reduce trade barriers and facilitate commerce, often a precursor to a more comprehensive pact.
Comprehensive Global Strategic Partnership: A broad-based alliance between nations covering multiple sectors like defense, economy, technology, and diplomacy, reflecting deep mutual trust and shared interests.
Foundational Agreements: A set of military pacts between the US and partner nations (LEMOA, COMCASA, BECA) that enable closer defense cooperation, logistics support, and secure information sharing.
Tariffs: Taxes imposed by a government on imported goods and services, typically used to protect domestic industries or generate revenue.
Generic Drugs: Pharmaceutical products that are equivalent to a brand-name drug in dosage, safety, strength, route of administration, quality, performance, and intended use, but are typically sold at a lower cost.
ASEAN: The Association of Southeast Asian Nations, a regional intergovernmental organization promoting economic, political, and security cooperation among its ten member states.
East Asia Summit (EAS): A regional forum of 18 countries, including ASEAN members, India, and the US, for strategic dialogue on political, security, and economic challenges in the Indo-Pacific.